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Okadaic acid-Parthenolide combination at subtoxic doses induces potent synergistic apoptotic 
effects in human retinoblastoma Y79 cells by upregulating PTEN. 
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Retinoblastoma is the most common intraocular malignancy afflicting children. The incidence is 
higher in developing countries, where treatment is limited and long-term survival rates are low. 
Vincristine, etoposide, and carboplatin -the agents commonly used in the treatment of 
retinoblastoma- determine side effects causing significant morbidity to pediatric patients and 
significantly limiting dosing. Thus, identifying new drugs and molecular targets to facilitate the 
development of novel therapeutics, and finding natural drug combinations to kill cancer cells by 
synergistically acting at subtoxic doses, may be a good goal. Here, we investigated the effects of 
two natural compounds, okadaic acid (OKA) and parthenolide (PN), in human retinoblastoma Y79 
cells. We showed that OKA/PN combination at subtoxic doses induces potent synergistic apoptotic 
effects accompanied by decrease in p-Akt, increase in the stabilized p53 forms and potent decrease 
in pS166–Mdm2. We also showed the key involvement of PTEN which, after OKA/PN treatment, 
potently increased before p53, suggesting that p53 activation was under PTEN action. PTEN-
knockdown increased p-Akt/ pS166Mdm2 over basal levels and significantly lowered p53, while 
OKA/PN treatment failed both to lower p-Akt and pS166–Mdm2 and to increase p53 below/over 
their basal levels respectively. OKA/PN treatment potently increased ROS levels while decreased 
those of GSH. Reducing cellular GSH by butathionine-sulfoximine treatment significantly 
anticipated the cytotoxic effect exerted by OKA/PN. The effects of OKA/PN treatment on both 
GSH content and cell viability were less pronounced in PTEN silenced cells than in control cells. 
 Our study reports for the first time both a synergistic apoptotic action between OKA and PN and the 
involvement of PTEN as key player in the apoptotic mechanism in human retinoblastoma Y79 cells. 
The results provide strong suggestion for combined inhibition of the PTEN/Akt/Mdm2/p53 
pathway. 
